Position in INVA
as of Jun 30, 2026
· filed Jul 17, 2026
Position Value
$205,911
+$11,516 QoQ
Shares Held
9,067
-39.4% QoQ
Ownership
0.013%
of shares outstanding
% of Portfolio
0.20%
of 13F equity value
Holder Rank
#214
of 306 holders
Holding Since
Mar 2023
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in INVA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Gallacher Capital Management LLC holds $2,342,787 across 8 Biotechnology names. INVA ranks #7 (8.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
|
10,486 | $570,543 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
5,264 | $412,013 | |
| 3 | GMAB |
Genmab A/S
|
14,240 | $391,172 | |
| 4 | ARGX |
Argenx SE
|
304 | $282,042 | |
| 5 | HRMY |
Harmony Biosciences Holdings, Inc.
|
6,666 | $242,709 | |
| 6 | BNTX |
BioNTech SE
|
2,448 | $227,786 | |
| 7 | INVA |
Innoviva, Inc.
This page
|
9,067 | $205,911 | |
| 8 | ANVS |
Annovis Bio, Inc.
|
5,705 | $10,611 |
All Filings in INVA
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $205,911 | 9,067 | Shares | Sole | 2026-07-17 | |
| 2023-09-30 | $194,395 | 14,965 | Shares | Sole | 2023-11-13 | |
| 2023-03-31 | $209,598 | 18,631 | Shares | Sole | 2023-05-12 | |
| No filing history on record for this holder in this stock. | ||||||